COVID-19与病毒性肺炎住院后肺实质异常的Meta分析
该系统综述与随机效应Meta分析纳入95项观察性研究(其中70项可合并,含60项SARS-CoV-2研究,中位随访3个月),评估COVID-19及其他病毒性肺炎住院幸存者随访12个月内CT及肺功能异常比例。SARS-CoV-2随访期炎症后遗症估计比例为50%(95%CI 0.41-0.58),纤维化后遗症为29%(95%CI 0.22-0.37),气体交换受损为38%(95%CI 0.32-0.44),高于限制性通气障碍的17%(95%CI 0.13-0.23)。
要点
- COVID-19住院幸存者随访CT炎症后遗症约50%、纤维化后遗症约29%。
- 肺功能气体交换受损约38%,高于限制性通气障碍约17%。
- 随访时间与炎症后遗症估计值显著负相关,与纤维化后遗症无显著关联。
核心结论
- COVID-19及其他病毒性肺炎住院后随访可见与肺实质疾病相符的后遗症。
- 因异质性高及研究病例组合和初始严重程度差异,估计值需谨慎解读。
研究设计与样本
- 系统综述与随机效应Meta分析,检索MEDLINE和Embase。
- 纳入成人SARS-CoV-2、SARS-CoV、MERS-CoV或流感肺炎住院后12个月内随访的研究。
- 95项研究纳入定性合成(98.9%为观察性),70项适合Meta分析,其中60项为SARS-CoV-2研究,中位随访3个月。
主要发现
- SARS-CoV-2随访期炎症后遗症总体估计比例为50%(95%CI 0.41-0.58;I2=95%)。
- 纤维化后遗症估计比例为29%(95%CI 0.22-0.37;I2=94.1%)。
- 气体交换受损估计占肺功能检查的38%(95%CI 0.32-0.44;I2=92.1%),高于限制性通气障碍的17%(95%CI 0.13-0.23;I2=92.5%)。
- 随访时间与炎症后遗症估计值显著相关(-0.036;95%CI -0.068至-0.004;p=0.029),与纤维化后遗症关联未达显著性(-0.021;95%CI -0.051至0.009;p=0.176)。
- 气体交换受损与限制性通气障碍均与随访时间无显著关联(p=0.207;p=0.864)。
临床怎么用
- 对COVID-19及其他病毒性肺炎住院幸存者随访时应关注CT肺实质异常及肺功能气体交换受损。
- 解读随访异常比例时需考虑研究间异质性及病例严重程度差异。
局限性
- 研究病例组合和初始严重程度存在差异。
- 绝大多数为观察性研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Persisting respiratory symptoms in COVID-19 survivors may be related to development of pulmonary fibrosis. We assessed the proportion of chest CT scans and pulmonary function tests consistent with parenchymal lung disease in the follow-up of people hospitalised with COVID-19 and viral pneumonitis. METHODS: Systematic review and random effects meta-analysis of proportions using studies of adults hospitalised with SARS-CoV-2, SARS-CoV, MERS-CoV or influenza pneumonia and followed up within 12 months. Searches performed in MEDLINE and Embase. Primary outcomes were proportion of radiological sequelae on CT scans; restrictive impairment; impaired gas transfer. Heterogeneity was explored in meta-regression. RESULTS: Ninety-five studies (98.9% observational) were included in qualitative synthesis, 70 were suitable for meta-analysis including 60 SARS-CoV-2 studies with a median follow-up of 3 months. In SARS-CoV-2, the overall estimated proportion of inflammatory sequelae was 50% during follow-up (0.50; 95% CI 0.41 to 0.58; I2=95%), fibrotic sequelae were estimated in 29% (0.29; 95% CI 0.22 to 0.37; I2=94.1%). Follow-up time was significantly associated with estimates of inflammatory sequelae (-0.036; 95% CI -0.068 to -0.004; p=0.029), associations with fibrotic sequelae did not reach significance (-0.021; 95% CI -0.051 to 0.009; p=0.176). Impaired gas transfer was estimated at 38% of lung function tests (0.38 95% CI 0.32 to 0.44; I2=92.1%), which was greater than restrictive impairment (0.17; 95% CI 0.13 to 0.23; I2=92.5%), neither were associated with follow-up time (p=0.207; p=0.864). DISCUSSION: Sequelae consistent with parenchymal lung disease were observed following COVID-19 and other viral pneumonitis. Estimates should be interpreted with caution due to high heterogeneity, differences in study casemix and initial severity. PROSPERO REGISTRATION NUMBER: CRD42020183139.
引用
- Fabbri L, Moss S, Khan FA, et al. Parenchymal lung abnormalities following hospitalisation for COVID-19 and viral pneumonitis: a systematic review and meta-analysis. Thorax. 2022. PMID: 35338102. doi:10.1136/thoraxjnl-2021-218275
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。